#184 - AMA #29: GLP-1 Agonists—The Future of Treating Obesity?

The Peter Attia Drive

Peter Attia, MD

Health & Fitness, Medicine, Fitness

4.7 • 7.3K Ratings

🗓️ 15 November 2021

⏱️ 14 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In this “Ask Me Anything” (AMA) episode, Peter and Bob discuss all things related to GLP-1 agonists—a class of drugs that are gaining popularity for the treatment of obesity. They cover the discovery of these peptides, their physiology, and what it is they do in their natural state. Next, Peter and Bob break down a recently published study which showed remarkable results for weight loss and other metabolic parameters using a once-weekly injection of the GLP-1 agonist drug semaglutide, also known as Ozempic, in overweight and obese patients. Finally, they compare results from the semaglutide study to results from various lifestyle interventions and give their take on the potential future of GLP-1 agonists.

If you’re not a subscriber and listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or on our website at the AMA #29 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

We discuss:

Remarkable results of a recent study in overweight adults [2:15];
Key background on insulin, glucagon and the incretin effect [4:00];
What is GLP-1 and how does it work? [16:30];
2021 semaglutide study: remarkable results, side effects, and open questions [30:00];
Semaglutide vs. lifestyle interventions: comparing results with semaglutide vs. lifestyle interventions alone [44:00];
Closing thoughts and open questions on the therapeutic potential of semaglutide [47:30]; and
More

Learn more: https://peterattiamd.com/
Show notes page for this episode: https://peterattiamd.com/ama29/
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/
Connect with Peter on Facebook | Twitter | Instagram.

Transcript

Click on a timestamp to play from that location

0:00.0	Hey everyone, welcome to a sneak peek, ask me anything, or AMA episode of the Drive Podcast.
0:16.5	I'm your host, Peter Atia.
0:18.3	At the end of this short episode, I'll explain how you can access the AMA episodes in full,
0:22.9	along with a ton of other membership benefits we've created.
0:25.9	Before you can learn more now by going to peteratia-md.com forward slash subscribe.
0:31.5	So without further delay, here's today's sneak peek of the Ask Me Anything episode.
0:39.8	Welcome to Ask Me Anything, episode number 29.
0:43.2	I'm joined once again by Bob Kaplan.
0:45.8	In today's episode, we discuss all things related to GLP1 agonists.
0:52.0	Before you say why the hell would you dedicate an entire episode to an acronym I've never
0:56.6	heard of, I would say fair question, but GLP1 agonists are the class of drugs that are
1:05.4	all the rage right now when it comes to understanding treatments for obesity.
1:09.6	So you may not have heard the term GLP1, but there's at least a decent chance you've
1:14.2	heard of ozempick or semaglutide.
1:17.6	And even if you haven't heard of those, I suspect you'll find this episode very interesting.
1:21.1	Earlier this year, a study was published in the New England Journal of Medicine that looked
1:26.1	at the treatment of patients with overweight or obesity who were non-diabetic using a once-weekly
1:33.0	injection of a drug called semaglutide, also known as ozempick.
1:36.8	And the results were quite frankly out of this world.
1:40.2	So we're going to go through that paper, but of course to get through that paper, you
1:43.6	need to understand the physiology and the history of how these peptides were discovered and
1:49.4	what it is they do in their natural state.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Peter Attia, MD, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Peter Attia, MD and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.